Bubendorf, Switzerland, Monday, March 23, 2015 - CIS Pharma welcomes Davide Panighetti, who reinforces the research team as a new synthesis chemist. Davide’s skills will boost the team working on proprietary polymer-drug carrier developed for antibody-drug conjugates and antibody-radionuclide conjugates. The polymer-drug carriers are based on the CIS Pharma's proprietary polymer technology allowing ADCs to be custom designed for delivery [...]
Paris, France, Wednesday to Thursday, February 11 to 12, 2015 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]
Bubendorf, Switzerland, Monday, January 12, 2015 - CIS Pharma has taken a strategic decision to extend its activity into the field of cancer treatments. The defined objective is to improve the potency of antibody-drug conjugates (ADCs). Having established a number of lead materials, the research team is now developing drug carriers that offer higher drug load per antibody as compared [...]
Bubendorf, Switzerland, October 12, 2014 – CIS Pharma signs development and licensing agreement with licensee. Having developed intracameral cefuroxime as a response to the clinical demand for such a product, CIS Pharma is proud to have signed a deal on the regulatory approval and distribution of its product. Also, the deal includes a license to CIS Pharma’s patent protected cefuroxime [...]
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.